Abstract:The association of cdk4 with D-type cyclins to form functional kinase complexes is comparatively inefficient. This has led to the suggestion that assembly might be a regulated step. In this report we demonstrate that the CDK inhibitors p21(CIP), p27(KIP), and p57(KIP2) all promote the association of cdk4 with the D-type cyclins. This effect is specific and does not occur with other cdk inhibitors or cdk-binding proteins. Both in vivo and in vitro, the abundance of assembled cdk4/cyclin D complex increases directly with increasing inhibitor levels. The promotion of assembly is not attributable to a simple cell cycle block and requires the function of both the cdk and cyclin-binding domains. Kinetic studies demonstrate that p21 and p27 lead to a 35- and 80-fold increase in K(a), respectively, mostly because of a decrease in K(off). At low concentrations, p21 promotes the assembly of active kinase complexes, whereas at higher concentrations, it inhibits activity. Moreover, immunodepletion experiments demonstrate that most of the active cdk4-associated kinase activity also associates with p21. To confirm these results in a natural setting, we examine the assembly of endogenous complexes in mammary epithelial cells after release from a G(0) arrest. In agreement with our other data, cyclin D1 and p21 bind concomitantly to cdk4 during the in vivo assembly of cdk4/cyclin D1 complexes. This complex assembly occurs in parallel to an increase in cyclin D1-associated kinase activity. Immunodepletion experiments demonstrate that most of the cellular cyclin D1-associated kinase activity is also p21 associated. Finally, we find that all three CIP/KIP inhibitors target cdk4 and cyclin D1 to the nucleus. We suggest that in addition to their roles as inhibitors, the p21 family of proteins, originally identified as inhibitors, may also have roles as adaptor proteins that assemble and program kinase complexes for specific functions.

CDK Inhibitors: Cell Cycle Regulators and Beyond

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

Immunomodulatory Effects of CDK4/6 Inhibitors

Cell-cycle inhibitors: three families united by a common cause

Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors

Functional Versatility of the CDK Inhibitor p57Kip2

New functional activities for the p21 family of CDK inhibitors.

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

Ubiquitylation and Proteasomal Degradation of the P21(Cip1), P27(Kip1) and P57(Kip2) Cdk Inhibitors

Cks1: Structure, Emerging Roles and Implications in Multiple Cancers

Ubiquitylation and Proteasomal Degradation of the P21cip1, P27kip1and P57kip2cdk Inhibitors

Inhibitors of cyclin-dependent kinases as cancer therapeutics

Development of Cell-Cycle Inhibitors for Cancer Therapy

Cooperation Between The Cdk Inhibitors P27(Kip1) And P57(Kip2) In The Control Of Tissue Growth And Development

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.

Cooperation between the <i>Cdk</i> inhibitors <i>p27<sup>KIP1</sup></i> and <i>p57<sup>KIP2</sup></i> in the control of tissue growth and development

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

A Novel Cycline/cyclina-Cdk Inhibitor Targets P27(kip1) Degradation, Cell Cycle Progression and Cell Survival: Implications in Cancer Therapy.

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

CYCLINS AND CELL CYCLE CHECKPOINTS

Cell cycle regulation and anticancer drug discovery